P188 Tick tock...where and when can we give toc? Review of COVID-19 patients receiving tocilizumab in a non critical care setting

Abstract

IntroductionThe REMAP-CAP trial demonstrated the positive effects of interleukin-6 receptor antagonists (tocilizumab and sarilumab), on mortality in COVID-19 patients managed in a critical care setting.1 Prior to this, adjuvant drug...